Increased fractalkine and vascular dysfunction in obesity and in type 2 diabetes. Effects of oral antidiabetic treatment.
Administration, Oral
Adult
Biomarkers
/ blood
Brachial Artery
/ drug effects
Case-Control Studies
Chemokine CX3CL1
/ blood
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ blood
Double-Blind Method
Female
Glyburide
/ administration & dosage
Humans
Hypoglycemic Agents
/ administration & dosage
Male
Metformin
/ administration & dosage
Middle Aged
Obesity
/ blood
Pilot Projects
Pioglitazone
/ administration & dosage
Time Factors
Treatment Outcome
Vasodilation
/ drug effects
Chemokines
Diabetes
Endothelium
Fractalkine
Obesity
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
Historique:
received:
13
10
2019
revised:
23
02
2020
accepted:
20
03
2020
pubmed:
1
4
2020
medline:
21
10
2020
entrez:
1
4
2020
Statut:
ppublish
Résumé
Activation of fractalkine and other chemokines plays an important role in atherogenesis and, in conjunction with endothelial dysfunction, promotes premature vascular damage in obesity and diabetes. We hypothesized that increased circulating fractalkine coexists with impaired vasomotor function in metabolically healthy or unhealthy obesity, and that treatment with antidiabetic drugs may impact these abnormalities in type 2 diabetes. Compared to lean subjects, in both obese groups the vasodilator responses to acetylcholine and sodium nitroprusside were impaired (both P < .001); ET
Identifiants
pubmed: 32224233
pii: S1537-1891(19)30293-9
doi: 10.1016/j.vph.2020.106676
pii:
doi:
Substances chimiques
Biomarkers
0
CX3CL1 protein, human
0
Chemokine CX3CL1
0
Hypoglycemic Agents
0
Metformin
9100L32L2N
Glyburide
SX6K58TVWC
Pioglitazone
X4OV71U42S
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106676Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None for all the authors.